Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04750278 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19
A Phase 2 study, sponsored by Foresee Pharmaceuticals Co..
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04750278 is a Phase 2 study that was terminated before completion, run by Foresee Pharmaceuticals Co.. The registered enrollment target is 90 participants.
The verdict
NCT04750278, a Phase 2 study, was terminated before completion, sponsored by Foresee Pharmaceuticals Co..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
Interventions
- DRUG Placebo
- DRUG FP-025 100 mg
- DRUG FP-025 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04750278
The ClinicalTrials.gov registry entry for NCT04750278 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Foresee Pharmaceuticals Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04750278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04750278 about?
NCT04750278 is a clinical study titled "A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19". This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
What is the current status of trial NCT04750278?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2021-04-06. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT04750278?
The interventions under investigation include: Placebo (DRUG), FP-025 100 mg (DRUG), FP-025 300 mg (DRUG).
Who is sponsoring clinical trial NCT04750278?
This trial is sponsored by Foresee Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.